Methods of using bacteria to treat infections
By treating Gram-negative bacteria to reduce their endotoxin activity, the treated bacteria are formed and used as multi-TLR agonists, the insufficient efficacy and toxicity of existing TLR agonists in therapeutic vaccines has been solved, and the HBV is achieved and effective inhibition and long-term therapeutic effects of HIV.
Patent Information
- Application Number
- CN201980062939.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-27
- Filing Date
- 2019-09-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-09-26
AI Technical Summary
Existing TLR agonists have problems with insufficient efficacy and excessive toxicity in therapeutic vaccines, making it difficult to effectively activate immune responses, especially when treating existing viral infections such as HBV and HIV, traditional methods require lifelong treatment and are difficult to cure.
By treating Gram-negative bacteria with polymyxin and glutaraldehyde, reducing their LPS-related endotoxin activity, forming treated bacteria that are able to maintain integrity, significantly reduce LPS levels, and in human immune cells Induce higher levels of cytokine secretion, reduce systemic toxicity, and is used as a multi-TLR agonist for treatment.
A significant inhibitory effect in HBV and HIV infection was achieved, especially after discontinuation of treatment, which can still show long-term inhibitory effects, and enhance antiviral effects when used in combination with standard care, reducing the toxicity and cost of treatment.
Smart Images

Figure CN112770764B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 737,762, filed on September 27, 2018, under 35 U.S.C. §119, the contents of which are incorporated herein by reference in their entirety. Background Art
[0003] For viral infections, such as hepatitis B (HBV) and human immunodeficiency virus (HIV), existing therapies can control viral replication, improve clinical status in most treated patients, and result in reduced mortality and morbidity. However, rebound viremia after discontinuation of treatment and the emergence of drug-resistant mutations hamper antiviral therapy. Most patients require lifelong treatment, and chronic HBV or HIV infection is rarely cured.
[0004] Cytokines and chemokines are known to play an important role in host defense against a variety of viral infections, including hepatitis and HIV. Interferon-α (IFN-α) is approved for the treatment of hepatitis B infection, and several other cytokines, including interferon-γ (IFN-γ), interleukin 12 (IL-12), interleukin 23 (IL-23), GM-CSF, and tumor necrosis factor-α (TNF-α), have been implicated in host defense against or treatment of viral infections, such as hepatitis and HIV.
[0005] Prophylactic vaccination against pathogens requires the provision of antigenic determinants from the pathogen and adjuvants that provide immune system danger signals or downstream effectors required to activate immune responses against pathogen antigens. Therapeutic vaccines designed to treat pre-existing infections depend on host recognition of pathogen antigenic determinants in existing infections and also require adjuvants or their downstream effectors to provide danger signal-mediated immune activation. In some cases, it is possible to enhance therapeutic vaccines by providing exogenous pathogen-derived antigens. Immune cells of both the innate and adaptive immune systems use pattern recognition receptors (PRRs) to sense danger in the form of pathogen-associated molecular patterns (PAMPs). The most prominent family of PRRs consists of Toll-like receptors (TLRs), which are present on essentially all immune cells. These receptors (TLR 1, 2, 3, 4, 5, 6, 7, 8, and 9) respond to products found in many different types of pathogens, including bacteria and viruses. Activation of TLR receptors leads to direct and indirect activation of immune cell function and immune responses. Direct activation occurs by promoting cell maturation, proliferation, and differentiation, while indirect activation occurs by inducing cytokine and chemokine secretion. The tenth TLR (TLR10) may play a negative regulatory role in immune function.
[0006] Due to the role of TLR in host-mediated anti-pathogen immune response, great efforts have been made to produce TLR agonist adjuvants and therapeutic agents for infection. A variety of monospecific, purified or synthesized TLR agonists have been produced and tested in preclinical and clinical settings. TLR agonists are used as adjuvants in preventive vaccines. However, although antipathogenic activity has been observed in therapeutic vaccine settings, these efforts have encountered major challenges. The problems encountered include lack of efficacy and excessive toxicity, which indicates that further improvements are needed to prevent and especially treat existing infections with TLR agonists.
[0007] Overview
[0008] Since both innate and adaptive immune responses need to be activated for optimal immune defense, and pathogens contain multiple TLR agonists and other danger signal-related components, a multi-TLR agonist therapeutic approach is considered necessary for optimal anti-infective (including antiviral) therapy. Gram-negative bacteria are known to contain multiple TLR agonists and induce important immune responses associated with TLR agonists, including cytokine secretion. However, wild-type Gram-negative bacteria containing high levels of the TLR-4 agonist lipopolysaccharide (LPS) or endotoxin are highly toxic when administered intravenously, primarily due to excessive cytokine secretion induced by immune cells. Gram-negative bacteria also contain agonists for TLR 1 / 2, 5, and 9, which can simultaneously stimulate the immune system and cause systemic toxicity.
[0009] The present invention surprisingly and unexpectedly found that treating Gram-negative bacteria with polymyxin and glutaraldehyde to reduce their endotoxin activity associated with LPS can kill bacteria, keep bacteria intact, and significantly reduce LPS levels, while increasing the ability of bacteria to induce cytokine secretion from human immune cells. This is unexpected, at least because it is believed that a significant reduction in LPS should also result in a significant reduction in the amount of each of the multiple cytokines released by immune cells exposed to the treated bacteria relative to untreated wild-type bacteria.
[0010] Surprisingly, as shown in Table 1, when tested in bacteria of the same concentration (untreated and treated), the treated bacteria induced higher levels of 8 of the 9 cytokines secreted by human immune cells relative to untreated wild-type bacteria, although the treated bacteria only had 4.94% of the LPS content in the untreated bacteria. In addition, despite the significant reduction in LPS, the cytokine levels induced by the treated bacteria were higher compared to the monospecific TLR agonists (Table 2). Compared to untreated wild-type bacteria, the reduction in endotoxin activity associated with LPS during treatment was about 75%-99% as measured by in vitro Limulus Amebocyte Lysate (LAL), which can lead to reduced toxicity. Without being bound by any particular theory, it can be expected that the intact structure of the treated bacterial cells can help prevent or minimize the release of free LPS into some compartments of the host object. The results show that compared to untreated bacteria or monospecific agonists, treated bacteria can induce a higher immune response, and systemic toxicity is reduced relative to untreated bacteria.
[0011] Animal studies further confirmed that the treated bacteria can inhibit existing viral infection with HBV and HIV. In addition, when compared to standard of care (e.g., Entecavir for HBV), the treated bacteria showed sustainable and significant inhibition long after cessation of treatment, although the initial inhibition may take longer to occur. It is also interesting that even though treatment with NSAIDs (e.g., indomethacin) alone did not show observable antiviral effects, combination with NSAIDs can synergistically improve the efficacy of the treated bacteria.
[0012] Thus, in one embodiment, the present invention provides a method for treating an infection in a patient in need thereof, the method comprising administering to the patient an effective amount of a composition comprising a plurality of intact and substantially non-viable Gram-negative bacterial cells that have been treated to result in at least a 75% reduction in lipopolysaccharide (LPS)-associated endotoxin activity.
[0013] In another embodiment, the present invention provides a method of preventing infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a plurality of intact and substantially non-viable Gram-negative bacterial cells and a pathogen-derived or pathogen-associated antigen, wherein the bacterial cells have been treated to result in at least a 90% reduction in lipopolysaccharide (LPS)-associated endotoxin activity.
[0014] In one embodiment, the present invention provides a method for preventing or treating an infection in a patient in need thereof. The method requires administering to the patient an effective amount of a composition comprising a plurality of intact and substantially non-viable Gram-negative bacterial cells that have been treated to result in a lipopolysaccharide (LPS)-associated endotoxin activity (active LPS) reduced by about 75% to 99% compared to untreated wild-type Gram-negative bacterial cells when measured by a Limulus amebocyte lysate (LAL) assay.
[0015] In some embodiments, the composition comprises about 0.01 to 100 ng of active LPS per kilogram of patient body weight. In some embodiments, the composition comprises about 0.02 to 20 ng of active LPS per kilogram of patient body weight. In some embodiments, the composition comprises about 0.1 to 10 ng of active LPS per kilogram of patient body weight.
[0016] In some embodiments, the composition comprises per 1x10 8 About 2 to 200 ng of active LPS per cell. In some embodiments, the composition comprises about 2 to 200 ng of active LPS per 1x10 8 About 10 to 120 ng of active LPS per cell. In some embodiments, the composition comprises about 10 to 120 ng of active LPS per 1x10 8 About 20 to 100 ng of active LPS per cell.
[0017] In some embodiments, the intact and substantially non-viable Gram-negative bacterial cells have been treated to result in a reduction of about 85% to 98% in LPS-associated endotoxins. In some embodiments, the intact and substantially non-viable Gram-negative bacterial cells have been treated to result in a reduction of about 90% to 98% in LPS-associated endotoxins.
[0018] In some embodiments, the infection is a viral infection, such as caused by a virus selected from Table A. In some embodiments, the viral infection is caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
[0019] In one embodiment, a pharmaceutical dosage form is also provided, comprising a plurality of intact and substantially non-viable Gram-negative bacterial cells that have been treated to result in a reduction in lipopolysaccharide (LPS)-associated endotoxin activity of about 75% to 99% as measured by a Limulus amebocyte lysate (LAL) assay compared to untreated wild-type Gram-negative bacterial cells, wherein the total LPS-associated endotoxin activity is equivalent to about 0.7 ng to 7000 ng active LPS, preferably equivalent to about 7 ng to 1400 ng active LPS.
[0020] In other embodiments, therapeutic compositions, vaccines, and dosage forms thereof are also described. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figures 1A-1D The effects of treatment with entecavir, treated bacteria (decoy bacteria), or a combination thereof on the inhibition of HBV DNA production in vivo are shown.
[0022] Figure 2 Decoy bacteria, but not entecavir, were shown to reduce HBeAg levels in vivo.
[0023] Figure 3A -D shows the results of a long-term study of inhibition of HBV DNA production in vivo.
[0024] Figure 4A -D shows the results of in vivo inhibition of HBsAg expression.
[0025] Figure 5A -D shows the results of in vivo inhibition of HBeAg expression.
[0026] Figure 6 The combination of indomethacin and decoy bacteria (with or without entecavir) was shown to suppress HBeAg expression in the liver of mice 27 weeks after cessation of treatment.
[0027] Fig. 7A -F shows immunohistochemical analysis of HBcAg expression in the liver of mice 27 weeks after cessation of treatment.
[0028] Fig. 8A -C shows suppression of HIV blood levels in HIV-infected humanized mice by standard of care treatment or treated bacteria.
[0029] Detailed description
[0030] The following description sets forth exemplary embodiments of the present technology. However, it should be appreciated that such description is not intended to limit the scope of the present disclosure, but is provided as a description of exemplary embodiments.
[0031] The following words, phrases, and symbols used in this specification are generally intended to have the meanings set forth below, unless otherwise indicated by the context in which they are used.
[0032] Compositions and methods for stimulating an immune response
[0033] The experimental examples of the present invention demonstrate that intact and non-viable Gram-negative bacterial cells treated to significantly reduce LPS-related endotoxin activity unexpectedly have an enhanced ability to induce cytokine secretion from immune cells. Therefore, such treated bacterial cells are suitable for providing a safe and effective method to stimulate an immune response in a subject. The immune response can be against bacterial, fungal, parasitic or viral infection.
[0034] Therefore, according to one embodiment of the present invention, a method of stimulating an immune response in a subject in need is provided. In another embodiment, a method for preventing or treating an infection in a patient in need is provided. In another embodiment, a method for treating an immunodeficiency in a patient in need is provided. In another embodiment, a method for vaccinating a subject at risk of infection is provided.
[0035] In some embodiments, the method requires administering to the subject / patient an effective amount of a composition comprising a plurality of treated bacterial cells disclosed herein. In some embodiments, the treated bacterial cells are intact and substantially non-viable Gram-negative bacterial cells that have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity and / or pyrogenicity.
[0036] Candidate bacterial organisms that can be used by the methods herein are Gram-negative and derived from wild-type organisms with endotoxin activity associated with LPS. The term "Gram-negative bacteria" refers to bacteria that do not retain the initial basic dye stain (e.g., crystal violet, which is part of the process known as Gram stain). In an exemplary Gram stain, cells are first fixed on a slide by heating and dyed with a basic dye (e.g., crystal violet), which is absorbed by Gram-negative bacteria and Gram-positive bacteria. The slide is then treated with a mordant (e.g., Gram iodine), which is combined with a basic dye (e.g., crystal violet) and captured in the cell. The cells are then washed with acetone or ethanol and then counterstained with another dye of a different color (e.g., safranin). Gram-positive organisms retain the initial violet color, while Gram-negative organisms are decolorized by washing organic solvents, so counterstaining is displayed. Exemplary Gram-negative bacteria include, but are not limited to, Escherichia spp., Shigella spp., Salmonella spp., Campylobacter spp., Neisseria spp., Haemophilus spp., Aeromonas spp., Francisella spp., Yersinia spp., Klebsiella spp., Bordetella spp., Legionella spp., Corynebacteria spp., Citrobacter spp., Chlamydia spp., spp.), Brucella spp., Pseudomonas spp., Helicobacter spp., and Vibrio spp.
[0037] Among the Gram-negative bacteria is the Enterobacteriaceae, a large family that includes many well-known pathogens, such as Salmonella, E. coli, Yersinia pestis, Klebsiella and Shigella, Proteus, Enterobacter, Serratia, and Citrobacter, along with many harmless commensals. Members of the Enterobacteriaceae family are called enterobacteriaceae because some members live in the intestines of animals.
[0038] In one embodiment, E. coli is selected as the organism. One specific strain contemplated is E. coli strain 2617-143-312, (Migula) Castellani and Chalmers ( 13070 TM Other E. coli strains that can be used include MG1655 ( 47076) and KY8284( 21272).
[0039] The Gram-negative organisms used in the methods herein need not be recombinant organisms containing or expressing DNA that is foreign to the wild-type form of the organism. However, in some embodiments, the organism may be modified to express some non-native molecules, including, for example, pathogen antigens or immunostimulatory proteins.
[0040] The term "lipopolysaccharide" (LPS) refers to a macromolecule composed of lipids and polysaccharides (glycophospholipids) linked by covalent bonds. LPS consists of three parts: 1) O antigen; 2) core oligosaccharide, and 3) lipid A. The O antigen is a repeating polysaccharide polymer attached to the core oligosaccharide and comprises the outermost domain of the LPS molecule. The core oligosaccharide is directly attached to lipid A and usually contains sugars such as heptose and 3-deoxy-D-mannosaccharide (also known as KDO, keto-deoxyoctanesulfonic acid). Lipid A is a phosphorylated glucosamine disaccharide linked to a variety of fatty acids. The fatty acids anchor the LPS in the outer membrane of the bacteria, and the rest of the LPS protrudes from the cell surface.
[0041] The endotoxic activity is localized in the lipid A domain of LPS and is therefore also referred to as "LPS-associated endotoxic activity". When bacterial cells are lysed by the immune system, membrane fragments containing LPS and lipid A are released into the circulation, causing fever (pyrogenicity) and potentially fatal shock (termed endotoxic or septic shock). The toxicity of LPS is expressed by lipid A through interaction with cells of the mammalian immune system, a process that results in the secretion of pro-inflammatory cytokines, including tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β), which can have fatal consequences for the host.
[0042] LPS-related endotoxin activity can be measured by methods known in the art, including, for example, the Limulus amebocyte lysate (LAL) assay, which utilizes blood from horseshoe crabs and can detect very low levels of LPS. The presence of endotoxin activity will result in clotting of the blood lysate due to amplification through an enzymatic cascade. Gel clotting, turbidity, and chromogenic forms of the LAL assay are commercially available.
[0043] Endotoxin activity assays based on enzyme-linked immunosorbent assays (ELISA) are also known, for example from Hyglos in Munich, Germany. The assay uses LPS-specific phage proteins attached to a solid phase to capture LPS, and after a wash step, the presence of LPS is determined by the addition of recombinant Factor C, which cleaves the compound when activated by LPS and then emits fluorescence. Factor C present in horseshoe crab amebocyte lysates is usually in the form of a zymogen and is the primer for the coagulation cascade that occurs in the LAL test.
[0044] Pyrogenicity refers to the ability of an agent to induce fever in a subject. Pyrogenicity can be measured as an increase in rectal temperature in rabbits in response to intravenously administered TLR agonists, biologics, or derivatives thereof.
[0045] A variety of methods can be used to reduce the endotoxin activity and / or pyrogenicity of Gram-negative organisms. The methods include treating the organism with an agent that binds to or disrupts the formation of LPS.
[0046] In one embodiment, the reduction of endotoxin activity or pyrogenicity is achieved by treating the bacterial organism with an antibiotic that inactivates endotoxins. Suitable such antibiotics are polymyxins, including polymyxin B or polymyxin E. It is within the capabilities of those skilled in the art to determine the amount and conditions of the antibiotics used for treatment. In one embodiment, polymyxin B or E can be used at a concentration of about 3 micrograms to 5,000 micrograms per milliliter. In another embodiment, the concentration of polymyxin can be about 200 micrograms to 5,000 micrograms per milliliter. In one embodiment, the antibiotic is applied to the bacterium for 10 minutes to 4 hours or about 30 minutes to about 3 hours.
[0047] In one embodiment, the bacteria are grown in the presence of magnesium (Mg) in the form of MgCl2. In one embodiment, the bacteria are treated with polymyxin in the presence of MgCl2 and at a temperature suitable for maintaining bacterial integrity. In one embodiment, the concentration of MgCl2 in the growth medium is about 0.5mM to about 5.0mM, or about 2mM, and the concentration of MgCl2 in the treatment medium is about 5.0mM to about 30mM, or about 20mM. In one embodiment, the temperature of the treatment medium is about 2°C to about 10°C, or about 4°C. Bacterial integrity is determined by the recovery efficiency in a well-defined pellet after centrifugation at 3,000xg for 10 minutes, and by electron microscopy or optical microscopy with Gram staining. In a preferred embodiment, the recovery rate of bacteria after treatment and washing is greater than about 80%, and the bacteria are intact by optical or electron microscopy.
[0048] In another embodiment, by using a known KDO2-lipid IV A The reduction of endotoxin activity is achieved by treating bacterial organisms with biosynthetic antibiotics. For example, Goldman et al., J Bacteriol. 170 (5): 2185-91, 1988, described antimicrobial agents including antimicrobial agents III, which specifically inhibit the activity of CTP: CMP-3-deoxy-D-mannuronate cytosine transferase and can be used to prevent the conversion of 3-deoxy-D-mannuronate (KDO) to LPS of Gram-negative organisms. With the cessation of LPS synthesis, bacterial growth also ceases. In the LPS precursor species lipid IV A Addition of KDO is the major pathway for lipid A-KDO formation in S. typhimurium and E. coli. In one embodiment, the antibiotic is antimicrobial III, and the Gram-negative bacteria are treated with a suitable amount (e.g., 5 micrograms per milliliter to 500 micrograms per milliliter) for a suitable time (e.g., 2 to 8 hours).
[0049] Likewise, the compound α-C-(1,5-anhydro-7-amino-2,7-dideoxy-D-mannan-heptapyranosyl)-carboxylate is known to inhibit 3-deoxy-D-mannan-suberate cytosine transferase (CMP-KDO synthase, a cytoplasmic enzyme that activates 3-deoxy-D-mannosyloctanoate (KDO) and incorporates LPS) (Nature. 1987 10-16; 329(6135): 162-4). Therefore, treatment of organisms with this compound can also reduce LPS-related endotoxin activity.
[0050] In another embodiment, reduction of endotoxin activity is achieved by treating the organism with an LPS inhibitor. For example, the bacterial cyclic lipopeptide surfactin has been shown to bind to lipid A, thereby inhibiting its activity (J Antibiot 2006 59(1):35-43).
[0051] In addition to endotoxins associated with LPS, various other components of Gram-negative organisms can also induce or contribute to pyrogenicity and septic shock, including outer membrane proteins, fimbriae, pili, lipopeptides, and lipoproteins (Jones, M., Int. J. Pharm. Compd., 5(4):259-263, 2001). Pyrogenicity can be measured by the rabbit method known in the art, including assessment of rectal temperature after intravenous injection of a putative pyrogen.
[0052] It has been found that treatment of Gram-negative organisms with a combination of polymyxin B and glutaraldehyde produced a 30-fold reduction in pyrogenicity as measured in rabbits. In one embodiment, 1,000 micrograms per milliliter (μg / mL) of polymyxin B and 1% glutaraldehyde were used to reduce pyrogenicity by 30-fold as measured in rabbits. Pyrogenicity was reduced by a combination of polymyxin B reaction with LPS and glutaraldehyde reactivity with LPS and other bacterial components. Glutaraldehyde also plays a dual role in this case by killing the bacteria.
[0053] Therefore, in one embodiment, a method for reducing endotoxin activity and pyrogenicity and killing Gram-negative bacterial microorganisms by treating bacteria with a combination of 1,000 μg / mL of polymyxin B and 1% of glutaraldehyde is provided. In another embodiment, Gram-negative bacteria are treated with a combination of polymyxin B in a dosage range of about 3 μg / mL to about 1,000 μg / mL and glutaraldehyde in a dosage range of about 0.1% to about 1.0%. In another embodiment, the dosage range of polymyxin B is about 100 μg / mL to about 1,000 μg / mL, and the dosage range of glutaraldehyde is about 0.5% to about 1.0%. In addition, Gram-negative bacteria can be treated with a dosage range of, for example, about 1,000 μg / mL to about 3,000 μg / mL of polymyxin B, and the dosage range of glutaraldehyde is about 0.5% to about 1.0%. In another aspect, Gram-negative bacteria can be treated with a dosage range of, for example, about 3,000 μg / mL to about 5,000 μg / mL of polymyxin B, while the dosage range of glutaraldehyde is about 0.5% to about 2.0%.
[0054] In some embodiments, the endotoxin activity associated with LPS (e.g., measured by LAL assay) of intact and substantially non-viable Gram-negative bacterial cells is reduced by at least about 70% compared to untreated wild-type. In some embodiments, the reduction is at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, or 99.98%. In some embodiments, the reduction is no greater than about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, 99.98%, or 99.99%. In some embodiments, the reduction is from about 70% to about 99.99%, from about 80% to about 99.99%, from about 90% to about 99.5%, or 99%, from about 91% to about 99%, from about 92% to about 98%, from about 93% to about 97%, from about 94% to about 96%, from about 94.5% to about 95.5%, from about 94% to about 97%, from about 95% to about 98%, from about 96% to about 99%, from about 97% to about 99.5%, or from about 98% to about 99.9%, without limitation.
[0055] In some embodiments, certain residual active LPS levels are preferred. For example, in some embodiments, in the compositions of the invention, each 1x10 8 There is about 1 to 200 ng of active LPS per cell. In some embodiments, per 1x10 8 In some embodiments, about 2 to 200 ng, about 5 to 150 ng, about 5 to 120 ng, about 10 to 120 ng, about 20 to 100 ng, about 20 to 50 ng, about 10 to 50 ng of active LPS is present per cell.
[0056] In some embodiments, the pyrogenicity (e.g., as measured by an in vivo rabbit assay) of intact and substantially non-viable Gram-negative bacterial cells is reduced by at least about 70% compared to untreated wild-type bacteria. In some embodiments, the reduction is at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, or 99.98%. In some embodiments, the reduction is no more than about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, 99.98%, or 99.99%. In some embodiments, the reduction is from about 70% to about 99.99%, from about 80% to about 99.99%, from about 90% to about 99.5%, or 99%, from about 91% to about 99%, from about 92% to about 98%, from about 93% to about 97%, from about 94% to about 96%, from about 94.5% to about 95.5%, from about 94% to about 97%, from about 95% to about 98%, from about 96% to about 99%, from about 97% to about 99.5%, or from about 98% to about 99.9%, without limitation.
[0057] As described above, in addition to endotoxins associated with LPS, various other components of Gram-negative organisms can also induce or promote pyrogenicity, such as outer membrane proteins, fimbriae, pili, lipopeptides, and lipoproteins. In some embodiments, intact and substantially non-viable Gram-negative bacterial cells are treated in such a manner that pyrogenicity is reduced by reducing LPS-associated endotoxin activity and reducing non-LPS-associated pyrogenicity, such as inactivating, removing, or blocking outer membrane proteins, fimbriae, pili, lipopeptides, or lipoproteins. In some embodiments, the reduction in non-LPS-associated pyrogenicity is at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, or 99.98%. In some embodiments, the reduction is no greater than about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, 99.98% or 99.99%.
[0058] According to the methods of the invention, the bacteria used for administration are rendered non-viable or substantially non-viable prior to or at the time of administration. "Non-viable" means that the organism is killed by treatment with an exogenous agent, and / or the organism contains a mutation that renders the organism incapable of surviving in a mammalian host. Substantially non-viable bacteria are strains whose viability is reduced by at least 80%, 85%, 90%, 95%, 99% or more.
[0059] Bacteria can be made inviable by treating with compounds such as polymyxins. When bacteria divide, polymyxins bind to LPS and interfere with membrane integrity, and reduce viability due to permeabilization of the cell envelope. If viability is reduced by this method, measures need to be taken to prevent cell lysis and keep the cells intact. Another method is to grow a bacterial strain with a conditional mutation in the LPS biosynthetic pathway, which is inhibited during growth and then transferred to non-permissive conditions that activate the mutation and destroy LPS biosynthesis. In each case, the procedure adopted is a procedure that makes bacteria inviable by determining the optimal treatment time or compound dosage in each case, so that viability has been lost while maintaining obvious bacterial cell integrity. In cases where non-viability is less than 100%, bacteria containing a mutation that prevents further proliferation of viable bacteria in a mammalian host (e.g., diaminopimelate auxotrophs, as described in Bukhari and Taylor, J. Bacteriol. 105(3):844-854, 1971 and Curtiss et al., Immunol. Invest. 18(1-4):583-596, 1989) can be used.
[0060] Diseases and conditions
[0061] The intact and substantially non-viable Gram-negative bacterial cells as disclosed herein can be used to enhance the immune system of a subject and thus can be used to prevent or treat diseases and disorders through an improved immune response. The intact and substantially non-viable Gram-negative bacterial cells as disclosed herein can also be used as a vaccine or immune adjuvant for subjects at risk of suffering from such diseases or disorders.
[0062] "Treatment" is a method used to obtain beneficial or desired results (including clinical results). Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., reducing one or more symptoms caused by the disease or condition, and / or reducing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and / or preventing or delaying the spread of the disease or condition (e.g., metastasis); and / or c) relieving the disease, i.e., causing regression of clinical symptoms (e.g., improving the disease state, partially or completely relieving the disease or condition, enhancing the efficacy of another drug, delaying the progression of the disease, improving the quality of life and / or prolonging survival).
[0063] "Prevention" refers to the treatment of any disease or condition that results in clinical symptoms of the disease or condition not developing. In some embodiments, bacterial cells can be administered to a subject (including a human) who is at risk for the disease or condition or has a family history of the disease or condition.
[0064] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the subject of treatment, observation, or experiment. The methods described herein can be used for human treatment and / or veterinary applications. In some embodiments, the subject is a mammal, such as a human, dog, cat, cow, sheep, etc. In one embodiment, the subject is a human.
[0065] In some embodiments, the disease or condition to be treated is an infectious disease. In some embodiments, the infection is caused by bacteria, fungi, parasites or viruses. In particular, the currently disclosed bacterial cells may be uniquely suitable for treating viral infections, such as infections caused by the viruses listed in Table A, optionally with a second anti-infective agent.
[0066] Table A. Virus list
[0067]
[0068]
[0069]
[0070]
[0071] In some embodiments, the disease treated is HBV infection. In some embodiments, the disease treated is HIV infection.
[0072] Dosage and schedule
[0073] In some embodiments, the level of LPS-associated endotoxin activity of intact and substantially non-viable Gram-negative bacterial cells administered to a subject can be determined. In one embodiment, the composition administered comprises about 0.01 to 200 ng of active LPS per kg of subject body weight.
[0074] The term "active LPS" refers to LPS in a composition that is capable of exhibiting endotoxin activity associated with LPS, e.g., as measured by the LAL assay, where 5-9 endotoxin units (EU) are considered equivalent to 1 ng of active LPS (based on a standard LPS preparation). The amount of active LPS in a composition can be described as the weight of uninhibited LPS that is capable of exhibiting the same level of endotoxin activity associated with LPS as the composition.
[0075] In some embodiments, the composition administered (eg, a composition comprising intact and substantially free of LPS-associated endotoxin activity of gram-negative bacterial cells) comprises about 0.01 to 150 ng of active LPS per kilogram of subject body weight. In some embodiments, the composition administered comprises about 0.02 to 150 ng, about 0.02 to 100 ng, about 0.05 to 100 ng, about 0.05 to 100 ng, about 0.05 to 50 ng, about 0.05 to 20 ng, about 0.1 to 20 ng, about 0.1 to 10 ng, about 0.1 to 5 ng, about 0.2 to 100 ng, about 0.2 to 50 ng, about 0.2 to 20 ng, about 0.2 to 10 ng, about 0.2 to 5 ng, about 0.3 to 90 ng, about 0.4 to 80 ng, about 0.5 to 70 ng, about 0.6 to 60 ng, about 0.7 to 50 ng, about 0.8 to 40 ng, about 0.9 to 30 ng, about 1 to 20 ng, about 2 to 15 ng, or about 3 to 12 ng of active LPS per kilogram of subject body weight.
[0076] The amount of active LPS applied to an object can vary according to the type and disease of the object. Some animals, such as mice, rats and dogs, may be able to utilize a higher amount of active LPS (e.g., 250-500 times compared to humans and rabbits). Therefore, in some embodiments, the composition applied comprises about 10 to 100,000 ng of active LPS per kilogram of object body weight. In some embodiments, the composition applied comprises about 20 to 50,000 ng, about 30 to 40,000 ng, about 40 to 30,000 ng, about 50 to 20,000 ng, about 0.7 to 10,000 ng, about 80 to 8,000 ng, about 90 to 7,000 ng, about 100 to 6,000 ng, about 200 to 5,000 ng or about 500 to 5000 ng of active LPS per kilogram of object body weight.
[0077] The number of bacterial cells administered to the subject can be determined based on the amount of active LPS required and the endotoxin activity level of the bacterial cells. The number can also depend on a variety of factors, including the age, weight, general health, sex, diet, administration time, route of administration, excretion rate, drug combination, and severity of a particular disease in the subject being treated. For example, the dosage can be expressed as the number of bacterial cells described herein per kilogram of subject body weight (mg / kg). A dosage of about 10,000 to 100,000,000 cells / kg may be suitable. In some embodiments, about 100,000 and 10,000,000 cells / kg may be suitable. In other embodiments, a dosage of 1,000,000 to 5,000,000 cells / kg may be suitable. It can also be based on body surface area (in square meters (m2 In some embodiments, about 10,000 to 100,000,000 cells / m 2 In some embodiments, about 100,000 and 10,000,000 cells / m 2 In other embodiments, 1,000,000 to 5,000,000 cells / m 2 Normalization to subject weight is particularly useful when adjusting doses between subjects of different sizes (e.g., when using the drug in children and adults simultaneously or converting an effective dose in a non-human subject (e.g., a dog) to a dose that is effective in a human subject).
[0078] Bacterial cells are usually administered after a disease or condition is diagnosed. In some embodiments, administration begins within 24 hours after infection or within 2, 3, 4, 5, 6, or 7 days after infection. In some embodiments, administration begins at least 24 hours after infection or at least 2, 3, 4, 5, 6, or 7 days after infection. In some embodiments, administration begins at any time before or after infection and can be performed as needed.
[0079] Administration may also begin prior to actual infection or prior to diagnosis of infection, as a preventive vaccine or prophylactic measure.
[0080] Combination therapy
[0081] In one embodiment, the bacterial cells disclosed herein can be used in combination with one or more other therapeutic agents used and / or developed to treat infection.
[0082] In some embodiments, one or more additional therapeutic agents may be inhibitors of cyclooxygenase (COX) enzymes, such as NSAIDS, including 6MNA, aspirin, carprofen, diclofenac, fenoprofen, flufenamate, flubiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, naproxen, niflumic acid, acid), piroxicam, sulindac sulfide, suprofen, tenidap, tolmetin, tomoxiprol, zomepirac, celexocib, etodolac, meloxicam, nimesulide, diisopropyl fluorophosphate, L745,337, NS398, rofecoxib ib), SC58125, S-aminosalicylic acid, ampyrone, diflunisal, nabumetone, acetaminophen, resveratrol, salicin, salicylaldehyde, sodium salicylate, sulfasalazine, sulindac, tamoxifen, ticlopidine, and valerylsalicylic acid.
[0083] In some embodiments, one or more additional therapeutic agents can be agonists of stimulatory immune checkpoints, such as CD27, CD28, CD40, CD122, CD137, OX40, GITR, and ICOS, or antagonists of inhibitory immune checkpoints, such as A2AR, B7-H3, B7-H4, CTLA-4, IDO, KIR, LAG3, PD-1, PD-L1, TIM-3, and VISTA.
[0084] Non-limiting examples of the one or more additional therapeutic agents also include abacavir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, balavir, cidofovir, combivir, dolutegravir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, ecoliever, famciclovir, fomivir, and serotonin. rsen), fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitors, type III interferon, type II interferon, type I interferon, interferon, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, nitazoxanide, nucleoside analogs, norvir, oseltamivir ( ), peginterferon alpha-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, protease inhibitors, raltegravir, ribavirin, rimantadine, ritonavir, pyramididine, saquinavir, sofosbuvir, stavudine, telaprevir, tenofovir, tenofovir disoproxil fumarate, disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, and zidovudine.
[0085] In one embodiment, the additional therapeutic agent is interferon alpha.
[0086] In some embodiments, Gram-negative organisms include polynucleotides encoding non-bacterial proteins (e.g., virus-specific antigens or immune system stimulating proteins). In some embodiments, Gram-negative organisms include polynucleotides encoding bacterial antigens, which may be derived from the same or different bacterial organisms, including Gram-positive organisms or other pathogens. As used herein, an antigen is any molecule that can be recognized by an immune response (antibody or immune cell).
[0087] Pharmaceutical compositions, dosage forms and administration methods
[0088] Various compositions suitable for treating a disease or condition have been described herein. In one embodiment, a composition or dosage form is provided comprising a plurality of intact and substantially non-viable Gram-negative bacterial cells that have been treated to result in a reduction of about 90% to 99% in lipopolysaccharide (LPS)-associated endotoxin activity as measured by a Limulus amebocyte lysate (LAL) assay compared to untreated wild-type Gram-negative bacterial cells, wherein the total LPS-associated endotoxin activity is equivalent to about 0.7 ng to 7,000 ng of active LPS, about 7 ng to 7,000 ng of active LPS, about 7 ng to 1400 ng of active LPS, or about 70 ng to 1400 ng of active LPS.
[0089] The composition can be used as an adjuvant or a biological response modifier. As used herein, the terms "adjuvant" and "biological response modifier" refer to any substance that enhances the immune response to an antigen. Therefore, adjuvants or biological response modifiers are used to stimulate the immune system to react more strongly to foreign antigens or to organisms that cause diseases or are associated with diseases. However, in some embodiments, recombinant forms of Gram-negative bacteria expressing, for example, viral proteins or human immune activation proteins (e.g., cytokines or chemokines) are contemplated for use in the disclosed methods. In another embodiment, purified immune activation proteins (e.g., cytokines or chemokines) are mixed with Gram-negative organisms before administration, or are administered before or after the Gram-negative organisms.
[0090] In some embodiments, the endotoxin activity associated with LPS (e.g., measured by LAL assay) of intact and substantially non-viable Gram-negative bacterial cells in the dosage form is reduced by at least about 70% compared to untreated wild-type bacteria. In some embodiments, the reduction is at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, or 99.98%. In some embodiments, the reduction is no greater than about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, 99.98%, or 99.99%. In some embodiments, the reduction is from about 70% to about 99.99%, from about 80% to about 99.99%, from about 90% to about 99.5%, or 99%, from about 91% to about 99%, from about 92% to about 98%, from about 93% to about 97%, from about 94% to about 96%, from about 94.5% to about 95.5%, from about 94% to about 97%, from about 95% to about 98%, from about 96% to about 99%, from about 97% to about 99.5%, or from about 98% to about 99.9%, without limitation.
[0091] In some embodiments, the pyrogenicity (e.g., as measured by an in vivo rabbit assay) of intact and substantially non-viable Gram-negative bacterial cells in the dosage form is reduced by at least about 70% compared to untreated wild-type bacteria. In some embodiments, the reduction is at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, or 99.98%. In some embodiments, the reduction is no more than about 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, 99.98%, or 99.99%. In some embodiments, the reduction is from about 70% to about 99.99%, from about 80% to about 99.99%, from about 90% to about 99.5%, or 99%, from about 91% to about 99%, from about 92% to about 98%, from about 93% to about 97%, from about 94% to about 96%, from about 94.5% to about 95.5%, from about 94% to about 97%, from about 95% to about 98%, from about 96% to about 99%, from about 97% to about 99.5%, or from about 98% to about 99.9%, without limitation.
[0092] In some embodiments, the reduction in non-LPS-related pyrogenicity is at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, or 99.98%. In some embodiments, the reduction is no greater than about 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.95%, 99.98%, or 99.99%.
[0093] In some embodiments, the viability of the substantially non-viable bacteria is reduced by at least 80%, 85%, 90%, 95%, 99% or more.
[0094] In some embodiments, the dosage form comprises about 10,000 to about 1 x 10 10 In some embodiments, the dosage form includes about 100,000 to about 1 x 10 8 In some embodiments, the dosage form includes about 1000,000 to about 1 x 10 7 In some embodiments, the dosage form comprises about 1x10 6 About 1x10 8 Such bacterial cells.
[0095] In some embodiments, the composition further comprises a second therapeutic / antiviral agent. In some embodiments, the second therapeutic agent is an NSAID (nonsteroidal anti-inflammatory drug). In some embodiments, the second therapeutic agent is a cyclooxygenase inhibitor, preferably selected from 6MNA, aspirin, carprofen, diclofenac, fenoprofen, flufenamate, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, naproxen, niflumic acid, piroxicam, sulindac sulfide, suprofen, tenidap, tolmetin, tomoxiprol, zomepirac, celecoxib, etodolac, meloxicam, nimesulide, diisopropyl fluorophosphate, L745,337, NS398, rofecoxib, SC58125, S-aminosalicylic acid, aminoantipyrine, diflunisal, nabumetone, paracetamol, resveratrol, salicin, salicylaldehyde, sodium salicylate, sulfasalazine, sulindac, tamoxifen, ticlopidine, valerylsalicylic acid, and combinations thereof.
[0096] In some embodiments, the second therapeutic agent is an agonist of a stimulatory immune checkpoint preferably selected from CD27, CD28, CD40, CD122, CD137, OX40, GITR, and ICOS. In some embodiments, the second therapeutic agent is an antagonist of an inhibitory immune checkpoint preferably selected from A2AR, B7-H3, B7-H4, CTLA-4, IDO, KIR, LAG3, PD-1, PD-L1, TIM-3, and VISTA.
[0097] In some embodiments, the second therapeutic agent is selected from abacavir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, lipitor, balavir, cidofovir, compivir, dolutegravir, darunavir, delavirdine, didanosine, docosanol, edoxuridine, efavirenz, emtricitabine, enfuvirtide, entecavir, ecoliever, famciclovir, fomivirsen, Fosamprenavir, foscarnet, phosphoacetate, ganciclovir, ibatacitabine, imunovir, iodoxuridine, imiquimod, indinavir, inosine, integrase inhibitors, type III interferon, type II interferon, type I interferon, interferon, lamivudine, lopinavir, loviride, maraviroc, morpholino, methylthiazone, nelfinavir, nevirapine, nexavir, nitazoxanide, nucleoside analogs, ritonavir, oseltamivir Peginterferon alfa-2a, penciclovir, peramivir, pulconaril, podophyllotoxin, protease inhibitors, raltegravir, ribavirin, rimantadine, ritonavir, pyramididine, saquinavir, sofosbuvir, stavudine, telaprevir, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trisoevir, tromantanamide, truvada, valacyclovir, valganciclovir, vicriviroc, adenosine, viramidine, zalcitabine, zanamivir, zidovudine, and combinations thereof.
[0098] In some embodiments, the second therapeutic agent is interferon alpha.
[0099] The compositions described herein can be formulated in a variety of ways for use in the methods described herein. In one embodiment, the composition comprises a biologically and pharmaceutically acceptable carrier as described throughout.
[0100] "Pharmaceutically acceptable carrier" refers to any diluent, excipient or carrier that can be used in the composition. Pharmaceutically acceptable carriers include ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (e.g., magnesium sulfate, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based materials, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, cryopreservatives (e.g., trehalose and mannitol and lanolin). Suitable drug carriers are described in the standard reference book Remington's Pharmaceutical Sciences, Mack Publishing Company in this field.
[0101] The composition is formulated for drug administration to mammals (preferably humans). Such pharmaceutical compositions of the present invention can be administered in a variety of ways, including parenteral administration. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
[0102] The sterile injectable form of the composition can be an aqueous or oily suspension. These suspensions can be prepared using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Acceptable vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives, can be used to prepare injections, such as natural pharmaceutically acceptable oils, such as olive oil or castor oil, particularly its polyoxyethylated form. These oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants, such as carboxymethyl cellulose or similar dispersants, which are generally used to prepare pharmaceutically acceptable dosage forms, including emulsions and suspensions. For formulation purposes, other commonly used surfactants, such as Tween, Span and other emulsifiers or bioavailability enhancers, which are commonly used to make pharmaceutically acceptable solid, liquid or other dosage forms, may also be used. The composition may be formulated for parenteral administration by injection (e.g., bolus or continuous infusion).
[0103] The pharmaceutical composition can be administered in single doses or multiple doses. The pharmaceutical composition can be administered by various methods, including, for example, rectal, buccal, intranasal and transdermal routes. In certain embodiments, the pharmaceutical composition can be administered by intra-arterial injection, intravenous, intraperitoneal, parenteral, intramuscular or subcutaneous administration.
[0104] One mode of administration is parenteral administration, such as by injection. Forms that can be incorporated into the pharmaceutical compositions described herein for administration by injection include, for example, aqueous or oil suspensions, or emulsions, sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, glucose or sterile aqueous solutions, and similar pharmaceutical vehicles.
[0105] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, trehalose, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose. The formulation may additionally include lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents. Example
[0106] The following examples are included to illustrate specific embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques that function well in the practice of the present invention and therefore can be considered to constitute specific modes of its implementation. However, in accordance with the present invention, it will be appreciated by those skilled in the art that many changes may be made in the specific embodiments disclosed and similar or similar results may still be obtained without departing from the spirit and scope of the present invention.
[0107] Example 1. Preclinical Efficacy Characterization of Systemically Administered Multiple Toll-Like Receptor (TLR) Agonists
[0108] This example tests the hypothesis that significantly reducing, but not completely eliminating, LPS activity and killing and stabilizing nonpathogenic Gram-negative bacteria can produce multi-TLR products that can be safely and effectively administered to induce anti-tumor immune responses.
[0109] Treatment of nonpathogenic Gram-negative E. coli with polymyxin B and glutaraldehyde under conditions of killing and stabilizing cells reduced LPS endotoxin activity and pyrogenicity by >90% ("treated bacteria", also referred to as "bait bacteria" or simply "bait"). Endotoxin activity and pyrogenicity were quantified using horseshoe crab amebocyte lysates and in vivo rabbit assays. Bacterial integrity was assessed by electron and light microscopy. Antitumor activity was determined using standard syngeneic and xenograft tumor models.
[0110] The treated bacteria had a 3-fold reduction in acute in vivo toxicity relative to untreated bacteria. Surprisingly, anti-tumor cytokine secretion induced by mouse and human peripheral blood mononuclear cells (PBMCs) was not impaired relative to untreated bacteria. Treatment with treated bacteria (iv) resulted in significant single-agent antitumor activity against orthotopic mouse colorectal cancer and metastatic mouse pancreatic cancer.
[0111] In mouse colorectal cancer models, synergistic combination activity, including eradication of established tumors, with therapeutic indices as high as 10-fold, was observed in combination with IL-2 or low-dose cyclophosphamide (LDC), using LDC in a subcutaneous (sc) murine non-Hodgkin lymphoma (NHL) model and using LDC plus rituximab in a sc human NHL model. Synergistic antitumor activity was also observed in combination with low-dose nonsteroidal anti-inflammatory drugs (NSAIDs) in a metastatic murine pancreatic cancer model. In addition, in a sc murine hepatocellular carcinoma model, tumor eradication was observed in combination with NSAIDs, and eradication was enhanced by the addition of anti-PD1 therapy. Optimal (80-100%) tumor eradication was demonstrated to be mediated by natural killer (NK), CD4 + and CD8 +T cell-mediated immunological memory determined by rejection of subsequent tumor challenge (80-100% and partial) was demonstrated in immunocompetent and innate-only conditions, respectively.
[0112] Example 2. Treated bacteria induce cytokine secretion
[0113] This example examines the ability of treated bacteria to induce cytokine secretion from human peripheral blood mononuclear cells.
[0114] Treatment of nonpathogenic Gram-negative E. coli with polymyxin B and glutaraldehyde under conditions of killing and stabilizing cells reduced LPS endotoxin activity and pyrogenicity by more than 90% ("treated bacteria", "bait bacteria" or simply "bait"), see Example 1 and U.S. Patent No. 9,265,804B2. Endotoxin activity and pyrogenicity were quantified using horseshoe crab amebocyte lysate and in vivo rabbit assay. Bacterial integrity was assessed by light microscopy after Gram staining.
[0115] Convert 10x10 to 1x10 8 Tenfold increments of untreated or treated bacteria were compared with 2.5x10 5 Human peripheral blood mononuclear cells (PBMCs) were incubated in RPMI medium containing 2.5 mM glutamine, 10% human serum and 1% penicillin and streptomycin at 37°C 5% CO2 for 48 hours. The supernatant was harvested by centrifugation at 1,000 rpm for 10 minutes and stored at -80°C. Luminex analysis of cytokine levels was performed using Millipore human cytokine / chemokine magnetic bead plates HCYTOMAG-60K and HSTCMAG-28SK. Cytokine levels were interpolated from the standard curve using a 5-point nonlinear regression analysis, where fit = (A + ((BA) / (1 + (((BE) / (EA)) * ((x / C) ^ D))))). The interpolated data were normalized to vehicle control or unstimulated control and analyzed. PBMCs were isolated from fresh normal peripheral blood leukapheresis (ALLCells, Alameda, CA) using a Ficoll gradient (Ficoll-Paque PLUS, Cat#17-144-02, density 1.077+ / -0.001 g / mL, from GE Healthcare Bio-Sciences, Pittsburgh, PA). The bacterial solvent was phosphate buffered saline (PBS) without calcium and 2 mM MgCl2.
[0116] The results presented are the peak levels of each cytokine determined using the same untreated or treated bacterial dose. The LPS content of the treated bacteria was 4.94% of that of the untreated bacteria, calculated on a bacterial basis, as measured by the in vitro Limulus amebocyte lysate (LAL) assay.
[0117] Table 1. Cytokine levels in PBMC induced by treated bacteria
[0118]
[0119] *The results presented are peak levels determined for each cytokine that occurred at the same dose of untreated and treated bacteria, with the exception of IFNγ, which peaked at a lower dose of untreated bacteria and was compared to the same dose of treated bacteria.
[0120] The activity of the treated bacteria was compared with several Toll-like receptor agonists (TLRa) and isolated LPS. The experiments were performed as described in Table 1. Toll-like receptor agonists (TLRa) were purchased from InvivoGen (San Diego, CA) and titrated as follows: CpG ODN 2006 (#tlrl-2006, 0.005 to 5 μM), Poly(I:C) (#tlrl-pic, 0.001 to 100 μg / mL), R848 (#tlrl-r848, 0.1 to 100 μg / mL) and E. coli LPS (#tlrl-pb5lps, 10 to 1x10 6 Pg / mL). TLR agonist stock solutions were prepared according to the manufacturer's recommendations until their recommended solubility limits were reached, and the results were peak cytokine levels determined for each TLRa and treated bacteria. The results are shown in Table 2 below.
[0121] Table 2. Cytokine induction compared to single TLR agonists
[0122]
[0123] Example 3. Animal experiment on treating viral infection with treated bacteria
[0124] This example tests the activity of treated bacteria, which may be prepared as described in Examples 1 and 2, in treating viral infections in animals.
[0125] The animal model of hepatitis B (HBV) infection used in this embodiment can be any of the following: hydrodynamic injection model, FVB / N model, adenovirus delivery model, adeno-associated virus model, woodchuck hepatitis virus infection model, chimpanzee model, Tupaia model, HBV transgenic mouse model, HBV-Trimera model and human liver chimera model. Suitable HIV animal models can also be used to test the activity of treated bacteria in preventing or treating HIV infection.
[0126] The treated bacterial preparations with the total amount of LPS activity measured by the horseshoe crab amebocyte lysate (LAL) assay in different ranges are administered to animals infected with viruses or expressing viral genes. In some animals, other immunostimulants or antivirals will be used as combined therapies. Animals that do not receive treatment and animals that receive other immunostimulants or antiviral treatments are used as controls. It is expected that in these animal models, the treated bacteria show effective antiviral activity.
[0127] Example 4. HBV Inhibition in Mice
[0128] Adeno-associated virus / hepatitis B virus (AAV / HBV) is a recombinant AAV carrying a replicable human HBV genome. The human HBV genome can be effectively delivered to mouse hepatocytes using the high liver function of genotype 8AAV. Infecting mice with strong immune capacity with AAV / HBV can lead to long-term HBV viremia, including the release of human HBV virions HBsAg and HBeAg into the blood, thereby mimicking chronic HBV infection in patients. The AAV / HBV model can be used to evaluate the in vivo activity of various types of anti-HBV drugs. In addition, this is a suitable model for evaluating immunomodulators (see, for example, Huang et al., Int. J. Onc. v39 pp1511-1519, 2011).
[0129] Genotype D rAAV8-1.3HBV was purchased from Beijing Wujia Molecular Medicine Research Institute (lot number A2018092406). The original virus of 1×10^12 viral genomes (vg) / mL was diluted to 5×10^11 v.g. / mL with sterile phosphate buffered saline (PBS). 31 days before the start of administration (day -31), each 5-week-old male C57BL / 6 mouse was injected with 1×10^11 v.g. AAV / HBV in 200 μL.
[0130] Blood samples (~100 μL) were collected into K2-EDTA-coated tubes by submandibular bleeding on days -17, -7, and -4. The samples were centrifuged at 7,000g (4°C) for 10 minutes to collect plasma. At least 40 μL of plasma samples were prepared to determine the level of HBV-DNA by qPCR, and the levels of HBs antigen (HBsAg) and HBe antigen (HBeAg) by enzyme-linked immunosorbent assay (ELISA). The remaining plasma samples were stored at -80°C for later analysis. Based on the plasma HBV DNA, HBsAg, HBeAg, and body weight on days -17, -7, and -4, mice with qualified viral infection levels were selected on day -1 and randomly divided into 7 groups of 5 mice each. On day -4, all mice were evenly distributed among the groups to ensure that there were no significant differences between the groups in HBV DNA, HBsAg, HBeAg levels, and body weight.
[0131] Bait bacteria were prepared as described in Example 1 and U.S. Pat. No. 9,265,804B2, with LPS-endotoxin activity ranging from about 2,000 to 6,000 endotoxin units (EU) per 10^9 killed bacterial cells or about 250 to 750 ng LPS. Animal groups were untreated (no treatment), treated with 0.005 mg / kg of entecavir (ETV) orally (po) daily on days 0-34, treated with 2x10^8 killed bacterial baits per mouse via the tail vein on days 1, 2, 8, 9, 15, 16, 22, 23, 29 and 30, or treated with ETV and bait. Plasma samples were obtained weekly and analyzed for HBV-DNA, HBsAg and HBeAg as described above. The HBV DNA (copy number), HBsAg, and HBeAg levels of the treated mice were compared with those of the untreated mice at each comparable time point by unpaired nonparametric Mann-Whitney statistical analysis.
[0132] Figure 1 shows that standard of care treatment (ETV) significantly suppressed HBV DNA production within 3 days of initiation of dosing, reducing plasma levels to the lower limit of quantification (120 copies / μL plasma) in 5 / 5 mice on day 28 of daily dosing (day 59 post infection) ( Figure 1B The decoy also significantly inhibited HBV DNA production, reducing plasma levels to the limit of quantification in 3 / 5 mice on day 28 of twice-weekly dosing (day 59 post-infection). Figure 1C ). The inhibitory effect of ETV+decoy on HBV DNA was similar to that of ETV alone, indicating that there was no antagonism at this point in compound administration ( Figure 1D ).
[0133] ETV did not have an inhibitory effect on HBsAg or HBeAg production. However, it was found that the decoy inhibited HBeAg production on day 28 of administration (day 59 after infection). Figure 2 ).
[0134] Thus, this example demonstrates that, like standard of care (ETV), bait bacteria can also significantly inhibit HBV replication, although the bait bacteria take longer to exhibit inhibitory activity, which is consistent with the immunological basis of the bait mechanism of action. However, unlike ETV, which only inhibits HBV DNA production, bait bacteria also have the advantage of inhibiting HBe antigen production.
[0135] Example 5. Long-term HBV suppression
[0136] This experiment was conducted to determine whether nonsteroidal anti-inflammatory drugs (NSAIDs) can enhance the antiviral activity of bait bacteria, as well as the potential toxic effects of ETV, bait and ETV+bait treatments if the antiviral activity of the bait is lost after treatment is stopped. The experiment was conducted as described in Example 4, except that the AAV / HBV virus was injected on day -29 relative to the start of administration. HBV-DNA, HBsAg and HBeAg levels in plasma were determined on days -15, -8 and -1 relative to the start of administration on day 0, and the ETV dose was increased to 0.1 mg / kg. In addition, all groups shown in Figures 3, 4, 5 and 6 took indomethacin (NSAID) (10 μg / mL in drinking water) every day. As in Example 4, administration was performed for 5 weeks, once a week and the plasma levels of HBV-DNA, HBsAg and HBeAg were determined every other week for 27 weeks after stopping treatment. Inhibitory activity was determined by comparing the treated group at each time point to the control group (indomethacin only) at the same time point using unpaired nonparametric Mann-Whitney statistical analysis.
[0137] After termination, the liver of each mouse was divided into multiple parts, which were immediately snap-frozen in liquid nitrogen and stored at -80°C after collection. Liver sections were used for HBV DNA detection, and other sections of each mouse liver were fixed in 10% neutral formalin (NBF) for about 24 hours and then transferred to routine dehydration and paraffin embedding. Paraffin blocks were sectioned for hematoxylin-eosin (H&E) staining and pathological analysis, as well as immunohistochemistry (IHC) analysis of HBsAg and HBcAg.
[0138] Figure 3AThis indicates that indomethacin alone cannot inhibit the production of HBV DNA. However, Figure 3 (B, C and D) shows that ETV, bait or ETV+bait inhibit HBV DNA production in the presence of indomethacin in a manner similar to that observed in the absence of indomethacin (Figure 1). No weight loss was observed with ETV treatment. A transient weight loss of 6% per day was observed in the first week of bait treatment (±ETV), 1.3% (without ETV) and 3.4% (+ETV) per day were observed in the second week of bait treatment, 0.8% (without ETV) and 2.0% (+ETV) per day were observed in the third week of treatment, and no weight loss was observed in the fourth and fifth weeks of bait treatment (±ETV).
[0139] Statistically significant suppression of HBV DNA was lost at termination (day 253) 27 weeks after cessation of ETV therapy ( Figure 3B ), but in the bait ( Figure 3C ) and Bait+ETV( Figure 3D ) group, the inhibitory effect was still statistically significant on day 253. This suggests that the bait has a longer-lasting inhibitory effect than ETV.
[0140] Indomethacin + ETV did not inhibit HBsAg or HBeAg relative to indomethacin alone ( Figure 4A , B and 5A, B). However, the addition of bait (i.e., indomethacin + bait or indomethacin + bait + ETV) suppressed the production of HBsAg and HBeAg relative to indomethacin alone ( Figure 4A , C, D and 5A, C, D). Since neither the decoy alone nor indomethacin alone could inhibit the production of HBsAg, these results suggest that there is a synergistic effect between the decoy and indomethacin with respect to the inhibition of HBsAg.
[0141] Figure 6 It was shown that in the presence of indomethacin, bait or bait + ETV, but not ETV, inhibited HBeAg expression in the liver of mice 27 weeks after cessation of treatment. Figure 7 shows IHC analysis of HBcAg expression in the liver of mice treated with bait vehicle (i.e., buffer used only in the bait composition) and compound. The combination of indomethacin and bait again reduced HBcAg expression in 2 of 5 mice compared to indomethacin alone, and the combination of indomethacin, bait and ETV reduced HBcAg expression in 5 of 5 mice relative to treatment with indomethacin + ETV or indomethacin + bait.
[0142] This example demonstrates that NSAIDs (e.g., indomethacin) do not inhibit HBV, but can significantly enhance the antiviral activity of bait bacteria in a synergistic manner. Bait bacteria showed longer and more sustained therapeutic effects compared to standard of care ETV. The combination of bait and ETV also showed significant improvements relative to each treatment alone, especially in long-term observation after cessation of treatment.
[0143] Example 6. Inhibition of HIV infection
[0144] In order to examine the potential of bait bacteria to inhibit human immunodeficiency virus (HIV) infection in vivo, the human immune system was reconstructed in NOD / Shi-scid / IL-2Rγnull-specific (NCG) immunodeficient female mice (Charles River), in which hematopoietic stem cells were isolated from human umbilical cord blood. After chemical myeloablation, mice were transplanted with umbilical cord blood-derived CD34+ hematopoietic stem cells and progenitor cells (French Blood Institute) (Manfroi et al., Can.Res.v77, pp1097-1107 2017). Implantation consisted of intravenous injection of 105CD34+ cells. Implantation levels were monitored by flow cytometry analysis of human CD45+ cells in whole blood leukocytes.
[0145] 14 weeks after implantation, 80 ng of HIV-1 (NL4-3 HIV1 / Clade B; X4-tropic virus) was inoculated into competent mice by intraperitoneal injection. Plasma viremia was determined by qRT-PCR at week 5. Other methods were described in Wenzel et al., J. Virol. Doi: 10.1128 / JVI.00907-19 (accepted manuscript published online August 2, 2019). Only mice with viral loads above 10 were used in the experiments. 4 At week 5, mice were randomly divided into groups based on the humanization rate, HIV load, and percentage of CD4+ T cells in the blood.
[0146] Groups were treated as follows: bait vehicle injected intravenously twice a week for 5 weeks; highly active antiretroviral therapy (HAART or triple therapy) consisting of 2.4 mg Lamivudine, 2.35 mg Tenofovir Disproxil, and 19.2 mg Raltegravir administered daily in food pellets for 6 weeks; or bait-killed bacteria (prepared as described in Example 4) injected intravenously (tail vein) at 6 x 10 7 , twice a week for 5 weeks.
[0147] Blood (100 μL) was collected from the retro-orbital sinus in a tube coated with EDTA every two weeks. Plasma was separated from cells by centrifugation and incubated at 56 ° C for 30 minutes to inactivate HIV, and then frozen at -80 ° C. Viral RNA was extracted from 40 μL of frozen inactivated plasma using an automatic nucleic acid purification device (Arrow, NorDiag) and a viral RNA extraction kit (DiaSorin, #12-08-02). HIV plasma viral load was determined by qRT-PCR using the "Generic HIV Charge Virale" kit (Biocentric, #TR001-440IC, Batch 0089 / 08A). The limit of sensitivity was set to 1000 copies / mL. Values below this threshold were considered undetected. The treatment group at each time point was compared with the vehicle group at the same time point by unpaired nonparametric Mann-Whitney statistical analysis to determine the inhibitory activity. The asterisk symbol indicates a statistically significant inhibitory effect.
[0148] Figure 8 demonstrates that HAART therapy suppresses HIV blood levels two weeks after starting treatment and persists for three weeks after stopping treatment ( Figure 8B The decoy bacteria did not suppress HIV levels during treatment, but suppression began to be observed 4 weeks after stopping treatment and persisted for 11 weeks (except at week 19) ( Figure 8C The delayed inhibitory response indicated that the bait bacteria were able to induce an immune response against HIV infection. One mouse death was recorded in each of the bait vehicle group and the group receiving HAART. No deaths were observed in the bait treatment group.
[0149] ***
[0150] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0151] The invention illustratively described herein may be suitably practiced in the absence of any element or elements, limitation or limitations not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like should be read broadly and without limitation. In addition, the terms and expressions employed herein have been used as terms of description rather than limitation, and it is not intended that such terms and expressions be used to exclude any equivalents of the features shown and described, or portions thereof, but it should be recognized that various modifications may be made within the scope of the invention as claimed.
[0152] Therefore, it should be understood that, although the present invention has been specifically disclosed by preferred embodiments and optional features, those skilled in the art may modify, improve and vary the embodiments of the present invention disclosed herein, and such modifications, improvements and variations are considered to be within the scope of the present invention. The materials, methods and examples provided herein represent preferred embodiments, are exemplary, and are not intended to limit the scope of the present invention.
[0153] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether the excised material is specifically recited herein.
[0154] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0155] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entirety to the same extent as if each were individually incorporated by reference. In case of conflict, the present specification, including definitions, will control.
[0156] It should be understood that although the present disclosure has been described in conjunction with the above embodiments, the foregoing description and examples are intended to illustrate rather than limit the scope of the present invention. For those skilled in the art to which the present invention belongs, other aspects, advantages and modifications within the scope of the present invention will be apparent.
Claims
1. Use of a composition for the preparation of a medicament for preventing or treating an infection in a patient in need thereof, the composition comprising a plurality of intact and substantially non-viable Escherichia coli cells which have been treated with polymyxin and glutaraldehyde to result in a 75% to 99% reduction in lipopolysaccharide (LPS)-associated endotoxin activity compared to untreated wild-type Escherichia coli cells when measured by a Limulus amebocyte lysate (LAL) assay, wherein the infection is caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
2. The use according to claim 1, wherein the composition comprises 0.01 to 100 ng of active LPS per kg of patient body weight.
3. The use according to claim 2, wherein the composition comprises 0.02 to 20 ng of active LPS per kg of patient body weight.
4. The use according to claim 2, wherein the composition comprises 0.1 to 10 ng of active LPS per kg of patient body weight.
5. The use according to claim 1, wherein the composition comprises 1 x 10 8 2 to 200 ng of active LPS per cell.
6. The use according to claim 5, wherein the composition comprises 1 x 10 8 10 to 120 ng of active LPS per cell.
7. The use according to claim 5, wherein the composition comprises 1 x 10 8 20 to 100 ng of active LPS per cell.
8. The use according to claim 1, wherein the intact and substantially non-viable E. coli cells have been treated with polymyxin and glutaraldehyde resulting in a reduction of LPS-associated endotoxins by 85% to 98%.
9. Use according to claim 8, wherein the intact and substantially non-viable E. coli cells have been treated with polymyxin and glutaraldehyde resulting in a 90% to 98% reduction in LPS-associated endotoxins.
10. The use according to claim 1, wherein the prevention or treatment further comprises administering a second therapeutic agent.
11. The use according to claim 10, wherein the second therapeutic agent is selected from 6-methoxy-2-naphthylacetic acid (6MNA), aspirin, carprofen, diclofenac, fenoprofen, flufenamate, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, naproxen, niflumic acid, piroxicam, sulindac sulfide, suprofen, tenidap, tolmetin, tomoxiprol, zomepirac, celecoxib, etodolac, meloxicam, nimesulide, diisopropyl fluorophosphate, 5-methanesulfonamido-6 -(2,4-difluorothienyl)-1-indanone (L745,337), N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide (NS398), rofecoxib, (5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluoromethyl)pyrazole) (SC58125), S-aminosalicylic acid, aminoantipyrine, diflunisal, nabumetone, paracetamol, resveratrol, salicin, salicylaldehyde, sodium salicylate, sulfasalazine, sulindac, tamoxifen, ticlopidine, valerylsalicylic acid, and combinations thereof.
12. The use according to claim 10, wherein the second therapeutic agent is selected from abacavir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, lipitor, balavir, cidofovir, compivir, dolutegravir, darunavir, delavirdine, didanosine, docosanol, edoxuridine, efavirenz, emtricitabine, enfuvirtide, entecavir, eco liever, famciclovir, fomivirsen, fosamprenavir, foscarnet, phosphoacetate, ganciclovir, ibatacitabine, imunovir, iodoxuridine, imiquimod, indinavir, inosine, integrase inhibitors, interferon, lamivudine, lopinavir, loviramide, maraviroc, morpholinoguanidine, methylthiazone, nelfinavir, nevirapine, nexavir, nitazoxanide, nucleoside analogs, ritonavir, oseltamivir Penciclovir, peramivir, pulconaril, podophyllotoxin, protease inhibitors, raltegravir, ribavirin, rimantadine, ritonavir, pyramididine, saquinavir, sofosbuvir, stavudine, telaprevir, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trisoevir, tromantanamide, truvada, valacyclovir, valganciclovir, vicriviroc, adenosine, viramidine, zalcitabine, zanamivir, zidovudine, and combinations thereof.
13. The use according to claim 10, wherein the second therapeutic agent is interferon alpha or pegylated interferon.
14. The use of claim 10, wherein the second therapeutic agent is a type III interferon, a type II interferon, or a type I interferon.
15. The use according to claim 10, wherein the second therapeutic agent is peginterferon alpha-2a.
16. The use according to any one of claims 1 to 15, wherein the E. coli cells contain an integrated or exogenous polynucleotide encoding a pathogen-specific antigen or an immune system stimulating protein.
17. The use according to any one of claims 1 to 15, wherein administration of the composition begins within 24 hours after infection or within 2 days, 3 days, 4 days, 5 days, 6 days or 7 days after infection.
18. The use according to any one of claims 1-15, wherein administration of the composition begins after at least 24 hours after infection or after at least 2 days, 3 days, 4 days, 5 days, 6 days or 7 days after infection.
19. The use according to any one of claims 1-15, wherein at least 90%, 95% or 100% of the E. coli cells are non-viable.
20. The use according to claim 1, wherein the polymyxin is polymyxin B or polymyxin E.
21. Use according to claim 20, wherein the treatment with the polymyxin is carried out at a temperature of 2°C to 10°C.
22. Use according to claim 21, wherein the treatment is carried out at a temperature of 4°C to 6°C.
23. The use according to claim 1, wherein the treatment is performed with polymyxin B in a dosage range of 3 mg / mL to 1,000 mg / mL and with glutaraldehyde in a dosage range of 0.1% to 1.0%.
Citation Information
Patent Citations
Compositions and methods for treatment of cancer using bacteria
US9265804B2
Compositions and methods for treatment of cancer using bacteria
CN104884073A
Probiotics composition for promoting removal of hepatitis B virus and application thereof
CN107184613A
Novel combination and use
CN107530397A
